SATURDAY 12 OCTOBER 2019

M01 Hematology

Malgorzata Mikulska, FECMM, Italy & Alessandro Busca, Italy

M02 Peadiatrics

Simone Cesaro, Italy & Adillia Warris, FECMM, UK

M03 Candida in the ICU

Matteo Bassetti, Italy & Jean-François Timsit, France

M04 Diagnostics/Laboratory

Alida Talento, Ireland & Michaela Lackner, FECMM, Austria

M05 Tropical

Arunaloke Chakrabarti, FECMM, India & Rita Oladele, FECMM, Nigeria

Time to switch rooms

PS 2.1 Candida

Christophe D'Enfert, France

PS 2.2 Aspergillus

Agostinho Carvalho, FECMM, Portugal

PS 2.3* Lineage-specific behavioural differences in isolates of Candida auris

Andrew Borman, United Kingdon

Coffee break

PS3.1 Mucormycosis

Oliver Cornely, FECMM, Germany

PS3.2 Endemic

George Thompson, USA

PS3.3 Rare moulds

Martin Hoenigl, FECMM, Austria

PS3.4 Rare yeasts

Sharon Chen, FECMM, Australia

Lunch

S05.1 Pre-transplant assessment

Blandine Rammaert, France

S05.2 Prophylaxis

John Perfect, USA

S05.3 Current guidelines

Shahid Husain, FECMM, Canada

S05.4 to be confirmed

S05.5* From the lung to the heart: fatal dissemination of azole-resistant Aspergillus fumigatus in a lung transplant patient

Rose-Anne Lavergne, France

S06.1 AML - in the era of FLT3 inhibitors

Russel Lewis, Italy

S06.2 ALL - there is a role for prophylaxis

Daniel Teschner, Germany

S06.3 Personalised medicine / approach by genetic risk factors

Pierre-Yves Bochud, Switzerland

S06.4 Baseline CT upon diagnosis of acute leukemia

Stefan Schwartz, Germany

S06.5* Investigating the impact of posaconazole prophylaxis on systematic fungal screening using galactomannan antigen, Aspergillus qPCR and Mucorales qPCR.

Anne-Pauline Bellanger, France

S07.1 Fluconazole and micafungin dosing in neonates

Roger Brüggemann, the Netherlands

S07.2 Antifungal susceptibility of paediatric candidemia

Zoi-Dorothea Pana, Greece

S07.3 Primary immunodeficiencies characterised by fungal infections

Fanny Lanternier, FECMM, France

S07.4 to be confirmed

S07.5* Isavuconazole use in pediatric hematoncologic patients: the Italian Association of Pediatric Hematology Oncology (AIEOP) experience

Nunzia Decembrino, Italy

S08.1 Anti-mold immune response: the impact of  the host, the pathogen and translational implications

Agostinho Carvalho, FECMM, Portugal

S08.2 Immunologic markers for diagnosis of invasive aspergillosis and other invasive mold infections

Carol Garcia-Vidal, Spain

S08.3 Immunologic markers for treatment stratification in invasive mold infection

S08.4 Multicenter study: Immunologic markers for treatment monitoring and diagnosis in invasive mold infection

Martin Hoenigl, FECMM, Austria

S08.5* Immunological characteristics of Broncho alveolar lavage in neutropenic patients with invasive aspergillosis

Claire Aguilar, France

S09.1 The global burden of chronic pulmonary aspergillosis

S09.2 Diagnosis of CPA. Where do we stand?

Aleksandra Barac, FECMM, Serbia

S09.3 Current treatment options for CPA

S09.4 Future directions

David Denning, FECMM, United Kingdom

S09.5* Raised amphotericin B MIC in Aspergillus fumigatus isolates from patients with Chronic Pulmonary Aspergillosis

Fiona Lynch, United Kingdom

Coffee break

S10.1 Phosphate acquisition and virulence in human fungal pathogens

S10.2 Hybrid histidine kinases: major sensing proteins in pathogenic fungi

Nicolas Papon, France

S10.3 Adapting to the host: how Candida causes bloodstream infection

Oliver Kurzai, Germany

S10.4* Evaluation of metabolic adaptations of Fonsecaea pedrosoi using tricyclazole and FTIR

Maria Lúcia Scroferneker, Brazil

S10.5* The analysis on the genes related to the biofilm formation of Candida glabrata

Xinyue Chen, Japan

S10.6* Biofilm formation by Histoplasma capsulatum in different culture mediums and oxygen atmospheres

Ana Marisa Fusco Almeida Brazil

S11.1 Olorofim - a novel mould-active antifungal (F2G

John Rex, FECMM, UK

S11.2 Fosmanogepix: a novel, broad spectrum antifungal therapy in clinical development, Amplyx

Michael Hodges, USA

S11.3 tba Scynexis

tba

S12.1 Frogs

Matthew Fisher, United Kingdom

S12.2 Cryptococcus gattii

Ferry Hagen, FECMM, the Netherlands

S12.3 Natural disasters

Tom Chiller, US

S12.4 Genomic sequencing

Marie Desnos, France

S12.5* Outbreak of fluconazole-resistant Candida parapsilosis in a hospital ward: arguments for clonal transmission and environmental persistence

Arnaud Fekkar, France

S13.1 Rasamsonia species and other emerging fungi in CF

Solène Le Gal, France

S13.2 Immunodiagnosis of Scedosporium/Lomentospora infection - lessons from immunoproteomic studies

Andoni Ramirez-Garcia, Spain

S13.3 Bacterial / Fungal interactions in the CF mucus

Françoise Botterel, France

S13.4* Morphology, growth and biofilm formation of the black yeast-like fungus Exophiala dermatitidis is influenced by Pseudomonas aeruginosa under in vitro cystic fibrosis conditions.

Lisa Kirchhoff, Germany

tba*

S13.6* Study of antigenic markers for serological detection of Scedosporium spp. in Cystic Fibrosis patients

Leire Martin-Souto, Spain

S14.1 Mycology teaching in Medical School - How much, what to choose, at what level

Peter Rath, FECMM, Germany

S14.2 Mycology teaching in Medical School  - Is student demography  important to what should be taught

Ester Segal, FECMM, Israel

S14.3 Specific courses outside the European Continent – The Indian Example

Ruth Ashbee, United Kingdom

S14.4 Teaching Clinical Laboratory Mycology–How and who is the audience

Sevtap Arikan-Akdagli, FECMM, Turkey

S14.5 The African example

Aude Sturny, France